# CT041-ST-01 (NCT04581473)

> Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04581473
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: CARsgen Therapeutics Co., Ltd.
- Conditions: Gastric Adenocarcinoma; Pancreatic Cancer; Gastroesophageal Junction Adenocarcinoma
- Interventions: CT041 autologous CAR T-cell injection; Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）
- Enrollment: 192
- Primary outcome: Phase Ib: Incidence of Treatment Related adverse events (AEs)
- Primary outcome: Phase Ib: Identification of Maximum Tolerated Dose (MTD)
- Primary outcome: Phase II: Progression-free survival (PFS), as assessed by IRC, of CT041 autologous CAR T-cell injection versus Physician's Choice

## Indexed commentary on CT041-ST-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 14
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ct041-st-01-nct04581473

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04581473", "email": "<work email>"}; the inbox owner confirms by the emailed link.